Page 3 - பேகிங் பல்கலைக்கழகம் புற்றுநோய் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 12, 2021 SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This is the third approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after fail

United statesSan franciscoHuang yiranPatricia keeganJunshi biosciencesGuo junEli lillyInstitute of microbiology chinese academy scienceShanghai jiao tong university school of medicineGuidelines of chinese society clinical oncologyIr teamUniversity cancer hospitalDrug administrationNational reimbursement drug listNational medical products administrationPr team